These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 14688091)
41. Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans. Yi HA; Panepinto JC; Jacobs A Microb Pathog; 2012 Jan; 52(1):25-30. PubMed ID: 21983597 [TBL] [Abstract][Full Text] [Related]
42. Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides. Klutts JS; Doering TL J Biol Chem; 2008 May; 283(21):14327-34. PubMed ID: 18347023 [TBL] [Abstract][Full Text] [Related]
43. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages. Chang ZL; Netski D; Thorkildson P; Kozel TR Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967 [TBL] [Abstract][Full Text] [Related]
49. Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Cleare W; Casadevall A Med Mycol; 1999 Aug; 37(4):235-43. PubMed ID: 10421858 [TBL] [Abstract][Full Text] [Related]
50. UDP-Glucuronic Acid Transport Is Required for Virulence of Li LX; Rautengarten C; Heazlewood JL; Doering TL mBio; 2018 Jan; 9(1):. PubMed ID: 29382737 [TBL] [Abstract][Full Text] [Related]
51. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties. Ramos CL; Fonseca FL; Rodrigues J; Guimarães AJ; Cinelli LP; Miranda K; Nimrichter L; Casadevall A; Travassos LR; Rodrigues ML Eukaryot Cell; 2012 Sep; 11(9):1086-94. PubMed ID: 22562469 [TBL] [Abstract][Full Text] [Related]
52. Cryptococcus neoformans is resistant to surfactant protein A mediated host defense mechanisms. Giles SS; Zaas AK; Reidy MF; Perfect JR; Wright JR PLoS One; 2007 Dec; 2(12):e1370. PubMed ID: 18159253 [TBL] [Abstract][Full Text] [Related]
54. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure. Urai M; Kaneko Y; Ueno K; Okubo Y; Aizawa T; Fukazawa H; Sugita T; Ohno H; Shibuya K; Kinjo Y; Miyazaki Y Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451 [TBL] [Abstract][Full Text] [Related]
55. Isolation and purification of antigenic components of Cryptococcus. Wozniak KL; Levitz SM Methods Mol Biol; 2009; 470():71-83. PubMed ID: 19089377 [TBL] [Abstract][Full Text] [Related]
56. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan. Duro RM; Netski D; Thorkildson P; Kozel TR Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451 [TBL] [Abstract][Full Text] [Related]
57. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106 [TBL] [Abstract][Full Text] [Related]
59. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Martinez LR; Moussai D; Casadevall A Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683 [TBL] [Abstract][Full Text] [Related]
60. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1. De Jesus M; Park CG; Su Y; Goldman DL; Steinman RM; Casadevall A Med Mycol; 2008 Mar; 46(2):153-62. PubMed ID: 18324494 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]